We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Dysregulation of Retinoic Acid Signaling in Stem Cells Spurs Tumor Growth

By LabMedica International staff writers
Posted on 05 Nov 2018
A team of cancer researchers identified the retinoic acid molecular signaling pathway as being a factor that helps to prevent the development of colorectal cancer.

Investigators at the Christiana Care Health System (Wilmington, DE, USA) were studying the factors controlling the differentiation of colon cancer stem cells (SCs) into undifferentiated tumor cells or, in some cases, into differentiated (non-cancerous) colon cells. More...
Since tumor development is driven by stem cell overpopulation, and in light of earlier findings that the enzyme aldehyde dehydrogenase (ALDH) was both a marker for SCs in many tissues and a key enzyme in retinoid acid (RA) signaling, the investigators examined RA signaling in normal and malignant colonic SCs.

The investigators analyzed normal and malignant colonic tissues and colorectal cancer (CRC) cell lines to see if retinoid receptors (RXR & RAR) were exclusively expressed in ALDH+ SCs, and if RA signaling changed during CRC development. Specifically, they determined whether RA signaling regulated cancer SC proliferation, differentiation, sphere formation, and population size.

Results published in the October 5, 2018, online edition of the journal Oncotarget revealed that RXR & RAR were expressed in ALDH+ colonic SCs, but not in normal cells. Western blotting/immunostaining of CRCs revealed that RA signaling components became overexpressed in parallel with ALDH overexpression, which coincided with the known overpopulation of ALDH+ SCs that occurs during, and drives, CRC development.

Treatment of SCs with all-trans retinoic acid (ATRA) was found to decrease proliferation, sphere formation, and ALDH+ SC population size and to induce differentiation. Thus, dysregulation of RA signaling in colonic SCs likely contributed to overpopulation of ALDH+ SCs and CRC growth.

“Our findings point to a number of possibilities for developing more effective stem cell targeting therapies for advanced colorectal cancer,” said senior author Dr. Bruce Boman, a senior research scientist at the Christiana Care Health System. “Our thinking has shifted to the insight that cancers originate in tissue stem cells through dysregulation or malfunction of the self-renewal process, and that cancer stem cells drive tumor growth. It follows that the optimal way to treat cancer (especially advanced cancer) is to eliminate cancer stem cells. We discovered that the retinoic acid or RA signaling pathway acts to induce differentiation of colon cancer stem cells and reduce cancer stem cell overpopulation, which puts the brakes on the primary mechanism that drives colon cancer development.”

Related Links:
Christiana Care Health System


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Laboratory Software
ArtelWare
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: A simple blood sample that allows DNA methylation could identify epigenetic biomarkers (Photo courtesy of 123RF)

Simple Blood Sample Could Identify Epigenetic Biomarkers to Predict CVD Risk in Type 2 Diabetes

People with type 2 diabetes face up to four times higher risk of cardiovascular events such as heart attacks, strokes, and angina compared to individuals without the condition. Yet, current tools used... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The new technology could predict who will benefit from immunotherapy (Photo courtesy of Max Delbrück Center)

New Technology Deciphers Immune Cell Communication to Predict Immunotherapy Response

A healthy immune system depends on complex communication between specialized cell types that detect, alert, and eliminate harmful threats. When these immune signaling pathways break down, the result can... Read more

Microbiology

view channel
Image: MycoMEIA Aspergillus Assay is the first FDA-cleared urine-based test for invasive aspergillosis (Photo courtesy of Pearl Diagnostics)

Urine-Based Assay Diagnoses Common Lung Infection in Immunocompromised People

Invasive Aspergillosis (IA), a life-threatening fungal infection, poses a serious threat to immunocompromised individuals, especially those with hematologic malignancies, transplants, or severe lung diseases.... Read more

Industry

view channel
Image: The acquisition of Exosome Diagnostics adds the ExoDx Prostate test to Mdxhealth’s portfolio (Photo courtesy of Bio-Techne)

Bio-Techne Divests Exosome Diagnostics to Reposition Product Portfolio

Bio-Techne Corporation (Minneapolis, MN, USA) has entered into an agreement with Mdxhealth SA (Irvine, CA, USA), which will acquire its Exosome Diagnostics Inc. (Waltham, MA, US) business, including the... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.